In this edition of HD Insights, we continue our focus on gene-targeting therapies for Huntington’s Disease and hear from influential scientists about their work to treat HD at the genetic source.

Issue No 17—Spring 2017

Load More

HD Insights thanks Teva for its ongoing support

Teva CNS is committed to continued research and development of its product portfolio and to the development of medicines aimed at meeting the specific needs of the patient communities it serves. Teva’s legacy in CNS is grounded in its commitment to ongoing collaboration with academia, medical institutions, and patient advocacy groups to find innovative solutions for patients who live with chronic and debilitating diseases.